Home Science MIRAM® Kit Clinical Studies News Team Careers Contact

Advancing Cancer Detection

We are pioneering a metabolism-based liquid biopsy. Our mission is to prevent cancer mortality through early detection.

Elypta MIRAM® Kit

Clinical studies

Elypta GAGome

We measure the GAGome — system biomarkers of tumor metabolism — then use machine learning to detect signatures of cancer noninvasively.

Elypta interim study results show glycosaminoglycan's potential to predict the risk of developing any-type cancer with a simple urine test

Elypta interim study results show glycosaminoglycan's potential to predict the risk of developing any-type cancer with a simple urine test

Results indicate that urine glycosaminoglycan profiles could identify people at higher risk of developing any type of cancer up to six years before diagnosis.

Elypta Appoints Dr. Eva Pisa to Board of Directors

Elypta Appoints Dr. Eva Pisa to Board of Directors

Elypta Receives ISO 13485:2016 Quality System Certification

Elypta Receives ISO 13485:2016 Quality System Certification

The Roddenberry Foundation Awards Elypta $1 Million Grand Prize

The Roddenberry Foundation Awards Elypta $1 Million Grand Prize

Double multi-cancer detection rate shown in the earliest stage using Elypta MIRAM® kit

Double multi-cancer detection rate shown in the earliest stage using Elypta MIRAM® kit

Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test

Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test

NyTeknik Top 33 swe startup

GEN Top 10 under 40

MIT Innovators undr 35

Backed by

Chalmers Ventures

Norrsken VC

We welcome partnerships with academia to explore clinical applications as well as industry for the development of companion diagnostics.

We welcome interest from investors and are happy to provide more information on our plans on request.

We are always looking to interact with top talents interested in joining our development team.